Radiation Oncology Clinical Trials
Phase 1
| Protocol Number | Protocol Title | Contacts | |
|---|---|---|---|
| MS201964-0001 2018-7823 |
A Multicenter, Open-Label, Dose Escalation Phase I Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of the DNA-PK Inhibitor M3814 in Combination with Avelumab with and without Palliative Radiotherapy in Participants with Selected Advanced Solid Tumors | PI: John Morris Coordinator: Bethany Fuhrman; fuhrmaba@uc.edu |
|
| AST-008-012 NCT03684785 IRB 2019-0158 |
A Phase I b/2 Study of AST-008 Combined with Pembrolizumab in Patients with Advanced Solid Tumors | PI: Trisha Wise-Draper Coordinator: Sheena Chandler; chandlsm@uc.edu |
|
| EMR200647-001 NCT02517398 IRB 2015-9180 |
A Phase I, open-label, multiple-ascending dose trial to investigate the safety, tolerability, pharmacokinetics, biological and clinical activity of MSB0011359C in subjects with metastatic or locally advanced solid tumors and expansion to selected indications | PI: John Morris Coordinator: Sheena Chandler; chandlsm@uc.edu |
|
| D6070C00001 NCT02503774 IRB 2017-3044 |
A Phase I Multicenter, Open-label, Dose-escalation and Dose-expansion Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Immunogenicity, and Antitumor Activity of MEDI9447 Alone and in Combination with durvalumab in Adult Subjects with Select Advanced Solid Tumors | PI: Trisha Wise-Draper Coordinator: Sheena Chandler; chandlsm@uc.edu |
|
| 3000-01-002 NCT03307785 IRB 2018-6839 |
Phase I b Dose-Finding Study of Niraparib, TSR-022, Bevacizumab, and Platinum-Based Doublet Chemotherapy in Combination with TSR-042 in Patients with Advanced or Metastatic Cancer | PI: Muhammad Riaz Coordinator: Sheena Chandler; chandlsm@uc.edu |
|
| 3000-01-004 NCT03329001 IRB 2018-7238 |
An Open-Label, Randomized-Sequence, Multicenter, Single-Crossover Study to Assess the Relative Bioavailability and Bioequivalence of Niraparib Tablet Formulation Compared to Niraparib Capsule Formulation in Patients with Advanced Solid Tumors. | PI: Trisha Wise-Draper Coordinator: Sheena Chandler; chandlsm@uc.edu |
|
| BBI-DSP7888-102CI NCT03311334 IRB 2018-1225 |
A Phase I b, Multicenter, Open-Label Study of DSP-7888 Dosing Emulsion in Combination with Immune Checkpoint Inhibitors Nivolumab or Atezolizumab in Adult Subjects with Advanced Solid Tumors | PI: Trisha Wise-Draper Coordinator: Sheena Chandler; chandlsm@uc.edu |
|
| H3B-6527-G000-101 NCT02834780 IRB 2016-8364 |
An Open-Label Multicenter Phase 1 Study to Evaluate the Safety, Pharmacokinetics and Pharmacodynamics of H3B-6527 in Subjects With Advanced Hepatocellular Carcinoma or Intrahepatic Cholangiocarcinoma | PI: John Morris Coordinator: Sheena Chandler; chandlsm@uc.edu |
|
Brain
| Protocol Number | Protocol Title | Contacts | |
|---|---|---|---|
| EAF151 NCT03115333 IRB 2018-1020 |
Change in Relative Cerebral Blood Volume as a Biomarker for Early Response to Bevacizumab in Patients with Recurrent Glioblastoma | PI: Rekha Chaudhary Coordinator: Max Mays; maysmw@uc.edu |
|
| IRB 2017-2183 | Feasibility Study of Hypofractionated Radiotherapy in the Setting of Recurrent Diffuse Intrinsic Pontine Glioma | PI: Luke Pater Coordinator: Hope Esslinger; Hope.Esslinger@uchealth.com |
|
| CG01-GBM NCT03632135 IRB 2018- | Phase II Trial of Observation versus Irradiation for a Gross Totally Resected Grade II Meningioma | PI: Rekha Chaudhary Coordinator: Max Mays; maysmw@uc.edu |
|
| NRG-BN003 NCT03180268 IRB 2018-0118 |
Phase II Trial of Observation versus Irradiation for a Gross Totally Resected Grade II Meningioma | Sub-I: Rekha Chaudhary Coordinator: Max Mays; maysmw@uc.edu |
|
| A071401 NCT02523014 IRB 2016-1035 |
TEMP CLOSED- Phase II trial of smo/akt/nf2 inhibitors in progressive meningiomas with smo/akt/nf2 mutations | PI: Rekha Chaudhary Coordinator: Max Mays; maysmw@uc.edu |
|
| CAE3313 NCT01894061 IRB 2013-7226 |
A Prospective Phase II Trial of NovoTTF-100A with Bevacizumab (Avastin) in Patients with Recurrent Glioblastoma | PI: Rekha Chaudhary Coordinator: Max Mays; maysmw@uc.edu |
|
| NRG-BN001 NCT02179086 IRB 2014-8049 |
Randomized Phase II Trial of Hypofractionated Dose-Escalated Photon IMRT or Proton Beam Therapy Versus Conventional Photon Irradiation with Concomitant and Adjuvant Temzolomide in Patients with Newly Diagnosed Glioblastoma | Sub-I: Luke Pater Coordinator: Max Mays; maysmw@uc.edu |
|
| UCCI-BN-16-01 NCT03122197 IRB 2016-8917 |
A Phase 0/I Exploratory Pharmacokinetic and Pharmacodynamics Study of Letrozole in Combination with Standard Therapy in Recurrent Gliomas. | PI: Trisha Wise-Draper Coordinator: Max Mays; maysmw@uc.edu |
|
| UCCI-BRAIN-16-01 NCT03278249 IRB 2017-0956 |
Feasibility Study of Modified Atkins Ketogenic Diet in the Treatment of Newly Diagnosed Malignant Glioma | PI: Rekha Chaudhary Coordinator: Max Mays; maysmw@uc.edu |
|
Breast
| Protocol Number | Protocol Title | Contacts | ||
|---|---|---|---|---|
| EA1131 2019-0644 | A Randomized Phase III Post-Operative Trial of Platinum Based Chemotherapy Vs. Capecitabine in Patients with Residual Triple-Negative Basal-Like Breast Cancer following Neoadjuvant Chemotherapy | PI: Neetu Radhakrishnan Coordinator: Laura Bundus; bundusla@uc.edu |
||
| D5336C00001 (VIOLETTE) 2018-6242 |
A Phase II, Open Label, Randomised, Multi-centre Study to Assess the Safety and Efficacy of Agents Targeting DNA Damage Repair in Combination with Olaparib versus Olaparib Monotherapy in the Treatment of Metastatic Triple Negative Breast Cancer Patients Stratified by Alterations in Homologous Recombinant Repair (HRR)-related Genes (including BRCA1/2) | PI: Neetu Radhakrishnan Coordinator: Laura Bundus; bundusla@uc.edu |
||
| Daiichi Sankyo DS8201-A-U301 IRB 2018-4169 |
A Phase III, Multicenter, Randomized, Open-Label, Active-Controlled Study of DS- 8201A, an Anti-HER2-Antibody Drug Conjugate, versus Treatment of Investigator’s Choice for HER2-Positive, Unresectable and/or Metastatic Breast Cancer Subjects Pretreated with Prior Standard of Care HER2 Therapies, including T-DM1 | PI: Mahmoud Charif Coordinator: Laura Bundus; bundusla@uc.edu |
||
| 3510 NCT02603341 IRB 2017-1626 |
Pragmatic Phase III Randomized Trial of Proton vs. Photon Therapy for Patients with Non-Metastatic Breast Cancer Receiving Comprehensive Nodal Radiation: A Radiotherapy Comparative Effectiveness (RADCOMP) Consortium Trial | PI: Teresa Meier Coordinator: Laura Bundus; bundusla@uc.edu |
||
| EA1151- TMIST NCT03233191 IRB 2018-2735 |
Tomosynthesis Mammographic Imaging Screening Trial (TMIST) | PI: Lawrence Sobel Coordinator: Monene Kamm; kammmm@ucmail.uc.edu |
||
| VVA-Laser | This is a randomized trial to determine the comparative effectiveness of the CO2RE laser device relative to topical lidocaine in treating dyspareunia among breast cancer survivors. | PI: James Whiteside Coordinator: Mollie Mosley; moselyme@ucmail.uc.edu |
||
| A221505 NCT03414970 IRB 2018-1652 |
Phase III Randomized Trial of Hypofractionated Post Mastectomy Radiation with Breast Reconstruction | PI: Teresa Meier Coordinator: Laura Bundus; bundusla@uc.edu |
||
| A011401 NCT02750826 IRB 2018-0248 |
Randomized Phase III Trial Evaluating the Role of Weight Loss in Adjuvant Treatment of Overweight and Obese Women with Early Breast Cancer | PI: Neetu Radhakrishnan Coordinator: Laura Bundus; bundusla@uc.edu |
||
| B-51/RTOG1304 NCT01872975 IRB 2013-3979 |
A Randomized Phase III Clinical Trial Evaluating Post-Mastectomy Chest wall and Regional Nodal XRT and Post -Lumpectomy Regional Nodal XRT in Patients with Positive Axillary Nodes before Neoadjuvant Chemotherapy who Convert to Pathologically Negative Axillary Nodes after Neoadjuvant Chemotherapy | Sub-I: Teresa Meier Coordinator: Laura Bundus; bundusla@uc.edu |
||
Gastrointestinal
| Protocol Number | Protocol Title | Contacts | |
|---|---|---|---|
| NRG-GI003 NCT03186898 IRB 2018-1655 |
A Phase III Randomized Trial of Protons Versus Photons for Hepatocellular Carcinoma | PI: Jordan Kharofa Coordinator: Patti Rose; Rosepi@uc.edu |
|
| SWOG S1815 IRB 2019-0578 |
A Phase III Randomized Trial of Gemcitabine, Cisplatin, and Nab-Paclitaxel Versus Gemcitabine and Cisplatin in Newly Diagnosed, Advanced Biliary Tract Cancers | PI: Olugbenga Olowokure Coordinator: Patti Rose; Rosepi@uc.edu |
|
| D6070C00005 NCT03611556 IRB 2018-2641 |
A Phase Ib/2 Study to Evaluate the Safety, Pharmacokinetics, and Clinical Activity of Oleclumab (MEDI9447) with or without Durvalumab in Combination with Chemotherapy in Subjects with Metastatic Pancreatic Ductal Adencarcinoma | PI: Olugbenga Olowokure Coordinator: Patti Rose; Rosepi@uc.edu |
|
| NRG-GI004 NCT02997228 IRB 2018-1656 |
Colorectal Cancer Metastatic dMMR Immuno-Therapy (COMMIT) Study: A Randomized Phase III Study of mFOLFOX6/Bevacizumab Combination Chemotherapy with or without Atezolizumab or Atexolizumab Monotherapy in the First-Line Treatment of Patients with Deficient DNA Mismatch Repair (dMMR) Metastatic Colorectal Cancer | PI: Jordan Kharofa Coordinator: Patti Rose; Rosepi@uc.edu |
|
| EA2165 NCT03233711 IRB 2018-4036 | A Randomized Phase II Study of Nivolumab After Combined Modality Therapy (CMT) in High Risk Anal Cancer | PI: Tahir Latif Coordinator: Patti Rose; Rosepi@uc.edu |
|
| 19244 NCT03289273 IRB 2018-0965 |
REFINE: Regorafenib observational study in hepatocellular carcinoma | PI: Olugbenga Olowokure Coordinator: Patti Rose; Rosepi@uc.edu |
|
| NRG-GI006 IRB 2019-0567 |
Phase III Randomized Trial of Proton Beam Therapy (PBT) Versus Intensity Modulated Photon Radiotherapy (IMRT) for the Treatment Of Esophageal Cancer | PI: Jordan Kharofa Coordinator: Patti Rose; Rosepi@uc.edu |
|
| NRG-GI003 NCT03186898 IRB 2018-1655 |
A Phase III Randomized Trial of Protons Versus Photons for Hepatocellular Carcinoma | PI: Jordan Kharofa Coordinator: Patti Rose; Rosepi@uc.edu |
|
| EA2142 NCT02595424 IRB 2017-7106 |
Randomized Phase II Study of Platinum and Etoposide versus Temozolomide and Capecitabine in Patients with Advanced G3 Non-Small Cell Gastroenteropancreatic Neuroendocrine Carcinomas | PI: Olugbenga Olowokure Coordinator: Patti Rose; Rosepi@uc.edu |
|
| UCCI-GI-16-01 NCT03018418 IRB 2016-5763 |
A Prospective Pilot Study to Evaluate the Feasibility of Intensity Modulated Proton Therapy in Reducing Toxicity in Anal Cancer | PI: Jordan Kharofa Coordinator: Patti Rose; Rosepi@uc.edu |
|
Genitourinary
| Protocol Number | Protocol Title | Contacts | |
|---|---|---|---|
| SWOG S1802 IRB 2019-0309 |
Phase III Randomized Trial of Standard Systemic Therapy (SST) versus Standard Systemic Therapy Plus Definitive Treatment (Surgery or Radiation) of the Primary Tumor in Metastatic Prostate Cancer | PI: Abhinav Sidana Coordinator: Melanie Gruen; gruenml@ucmail.uc.edu |
|
| EOVIST IRB 2016-4426 |
Gadoxetate Sodium Enhanced Magnetic Resonance Imaging (MRI) as a Biomarker for Aggressive Prostate Cancer | PI: Sadhna Verma Coordinator: Melanie Gruen; gruenml@ucmail.uc.edu |
|
| NRG-GU006 NCT03371719 IRB 2018-6243 |
A Phase II, Double-Blinded, Placebo-Controlled Randomized Trial of Salvage Radiotherapy with or without Enhanced Anti-Androgen Therapy with Apalutamide in Recurrent Prostate Cancer. | PI: Jordan Kharofa Coordinator: Melanie Gruen; gruenml@ucmail.uc.edu |
|
| IRB 2017-1091 NCT03564275 |
University of Cincinnati Proton Boost for Prostate Cancer Utilizing MR Imaging | PI: William Barrett Coordinator: Hope Esslinger; Hope.Esslinger@uchealth.com |
|
| EA8143 NCT03055013 IRB 2017-4426 |
A Phase III RandOmized Study Comparing PERioperative Nivolumab vs. Observation in Patients with Localized Renal Cell Carcinoma Undergoing Nephrectomy (PROSPER RCC) |
PI: John Morris Coordinator: Melanie Gruen; gruenml@ucmail.uc.edu |
|
Gynecology Oncology
| Protocol Number | Protocol Title | Contacts | |
|---|---|---|---|
| 2017C0128 OPTEC 2019-0544 |
Ohio Prevention and Treatment of Endometrial Cancer (OPTEC) | PI: Caroline Billingsley Coordinator: Valerie Hagood hagoodve@ucmail.uc.edu |
|
| Bio-Data-16-01 | Using Novel Objective Bio-data to Improve Quality of Life Assessment in Patients Undergoing Cytotoxic Chemotherapy: An Interventional Pilot StudyIII or IV Ovarian, Fallopian Tube, or Primary Peritoneal Cancer | PI: Thomas Herzog Coordinator: Valerie Hagood hagoodve@ucmail.uc.edu |
|
| NRG-GY005 NCT02502266 |
A Randomized Phase II/III study of the combination of Cediranib and Olaparib compared to Cediranib or Olaparib alone, or Standard of care chemotherapy in women with recurrent platinum-resistant or -refractory ovarian, fallopian tube, or primary peritoneal cancer (COCOS) | PI: Thomas Herzog Coordinator: Valerie Hagood hagoodve@ucmail.uc.edu |
|
| NRG-GY006 NCT02466971 | A Randomized Phase II Trial of Radiation Therapy and Cisplatin Alone or in Combination with Intravenous Triapine in Women with Newly Diagnosed Bulky Stage IB2, Stage II, IIIB, or IVA Cancer of the Uterine Cervix or Stage II-IVA Vaginal | PI: Thomas Herzog Coordinator: Valerie Hagood hagoodve@ucmail.uc.edu |
|
| GOG0238
NCT00492778 |
A randomized trial of pelvic irradiation with or without concurrent weekly cisplatin in patients with pelvic-only recurrence of carcinoma of the uterine corpus | PI: Thomas Herzog Coordinator: Valerie Hagood hagoodve@ucmail.uc.edu |
|
| GOG0263 NCT01101451 |
Randomized Phase III Clinical Trial of Adjuvant Radiation Versus Chemoradiation in Intermediate Risk, Stage I/IIA Cervical Cancer Treated with Initial Radical Hysterectomy and Pelvic Lymphadenectomy | PI: Thomas Herzog Coordinator: Valerie Hagood hagoodve@ucmail.uc.edu |
|
Head and Neck
| Protocol Number | Protocol Title | Contacts | |
|---|---|---|---|
| ISA101b-HN-01-17 NCT03258008 IRB 2018-4826 | A Randomized, Double-blind, Placebo-Controlled, Phase II Study of Cemiplimab Versus the Combination of Cemipilmab with ISA101b in the Treatment of Subjects with HPV16- Positive Platin-Resistant Oropharyngeal Cancer (OPC) | PI: Muhammad Riaz Coordinator: Aubrey Steele; steeleab@uc.edu |
|
| XL184-311 NCT03690388 IRB 2018-6366 |
A Phase III, Randomized, Double-Blind, Placebo-Controlled Study of Cabozantinib (XL184) in Subjects with Radioiodine-Refractory Differentiated Thyroid Cancer who have progressed after Prior VEGFR-Targeted Therapy. |
PI: David Steward Coordinator: Aubrey Steele; steeleab@uc.edu |
|
| EA3163 NCT03493425 IRB 2018-5130 |
Phase II randomized trial of neo-adjuvant chemotherapy followed by surgery and post- operative radiation versus surgery and post-operative radiation for organ preservation of T3 and T4a nasal and paranasal sinus squamous cell carcinoma (NPNSCC) | PI: Vinita Takiar Coordinator: Aubrey Steele; steeleab@uc.edu |
|
| UCCI-HN-17-02 NCT03691714 IRB 2018-0252 |
An open-label, phase II study of Durvalumab (MEDI4736) in combination with Cetuximab in previously treated recurrent or metastatic head and neck squamous cell carcinoma (HNSCC) | PI: Trisha Wise-Draper Coordinator: Aubrey Steele; steeleab@uc.edu |
|
| NRG-HN004 NCT03258554 IRB 2018-0254 |
Randomized Phase II/III Trial of Radiotherapy with Concurrent MEDI4736 (Durvalumab) Vs. Radiotherapy with Concurrent Cetuximab in Patients with Stage III-IVB Head and Neck Cancer with a Contraindication to Cisplatin | Sub-I: Vinita Takiar Coordinator: Aubrey Steele; steeleab@uc.edu |
|
| NRG-HN001 NCT02135042 IRB 2014-4045 |
Randomized Phase II and Phase III Studies of Individualized Treatment for Nasopharyngeal Carcinoma Based on Biomarker Epstein Barr Virus (EBV) Deoxyribonucleic Acid (DNA) | Sub-I: Vinita Takiar Coordinator: Aubrey Steele; steeleab@uc.edu |
|
| RTOG 1008 NCT01220583 IRB 2012-4268 |
A Randomized Phase II Study of Adjuvant Concurrent Radiation and Chemotherapy versus Radiation Alone in Resected High-Risk Malignant Salivary Gland Tumors | Sub-I: Vinita Takiar Coordinator: Aubrey Steele; steeleab@uc.edu |
|
| UCCI-HN-15-01 NCT02641093 IRB 2015-6798 |
Phase II investigation of adjuvant combined cisplatin and radiation with pembrolizumab in resected HNSCC | PI: Trisha Wise-Draper Coordinator: Aubrey Steele; steeleab@uc.edu |
|
| CDX3379-04 NCT03254927 IRB 2018-0968 |
A Phase II, Mutlicenter, Open-label Study to Evaluate the Efficacy and Safety of CDX- 3379 in Combination with Cetuximab in Patients with Advanced Head and Neck Squamous Cell Carcinoma | PI: Trisha Wise-Draper Coordinator: Aubrey Steele; steeleab@uc.edu |
|
| UCCI-HN-17- 01/CA209-997 NCT03355560 IRB 2017-2824 |
A Single Arm Phase II Study of Adjuvant Nivolumab after salvage resection in head and neck squamous cell carcinoma patients previously treated with definitive therapy | PI: Trisha Wise-Draper Coordinator: Aubrey Steele; steeleab@uc.edu |
|
Hematology
| Protocol Number | Protocol Title | Contacts | |
|---|---|---|---|
| AML003 NCT03504410 IRB 2018-7758 |
Phase III Multicenter Open-Label Randomized Trial to Evaluate Efficacy and Safety of CPI-613 in Combination with High Dose Cytarabine and Mitoxantrone (CHAM) Compared to High Dose Cytarabine and Mitoxantrone (HAM) in Older Patients (≥60 years) with Relapsed/Refractory Acute Myeloid Leukemia (AML) | PI: Zartash Gul Coordinator: Michelle Nguyen; nguyenmt@uc.edu |
|
| BL-8040-SCM-301 NCT03246529 IRB 2018-1226 |
A Phase III, Randomized, Double-Blinded, Placebo-Controlled, Multicentre Study Evaluating The Safety, Tolerability and Efficacy of Combination Treatment of BL-8040 and G-CSF as Compared to Placebo and G-CSF for the Mobilization of Hematopoietic Stem Cells for Autologous Transplantation in Subjects with Multiple Myeloma - The Genesis Study | PI: Tahir Latif Coordinator: Michelle Nguyen; nguyenmt@uc.edu |
|
| UCCI-HEM-17-01 NCT03688451 IRB 2017-5730 |
Feasibility and safety of Intrathecal Rituximab added to standard Intrathecal prophylaxis to prevent CNS relapse for CD 20 positive Non Hodgkin Lymphoma | PI: Tahir Latif Coordinator: Michelle Nguyen; nguyenmt@uc.edu |
|
| 2017-1 NCT03394755 IRB 2017-5650 |
A Phase I, Multi-Center, Open-Label, Dose Escalation Study of Thrombosomes® in Bleeding Thrombocytopenic Patients in Three Cohorts | PI: Jose Cancelas Coordinator: Michelle Nguyen; nguyenmt@uc.edu |
|
Lung
| Protocol Number | Protocol Title | Contacts | |
|---|---|---|---|
| A151216 NCT02194738 IRB 2015-0131 |
Adjuvant Lung Cancer Enrichment Marker Identification and Sequencing Trial (ALCHEMIST) | PI: John Morris Coordinator: Bree Kinne; kinnebm@ucmail.uc.edu |
|
| A081105 NCT02193282 IRB 2015-0135 |
Randomized study of erlotinib vs observation in patients with completely resected epidermal growth factor receptor (EGFR) mutant non-small cell lung cancer (NSCLS) | PI: John Morris: Coordinator: Bree Kinne; kinnebm@ucmail.uc.edu |
|
| E4512 NCT02201992 IRB 2015-0134 |
A Phase III Double-Blind Trial for Surgically Resected Early Stage Non-Small Cell Lung Cancer: Crizotinib versus Placebo for Patients with Tumors Harboring the Anaplastic Lymphoma Kinase (ALK) Fusion Protein | PI: John Morris Coordinator: Bree Kinne; kinnebm@ucmail.uc.edu |
|
| EA5142 NCT02595944 IRB 2016-6078 |
Adjuvant Nivolumab in Resected Lung Cancers (ANVIL)-A Randomized Phase III Study of Nivolumab After Surgical Resection and Adjuvant Chemotherapy in Non-Small Cell Lung Cancers | PI: John Morris Coordinator: Bree Kinne; kinnebm@ucmail.uc.edu |
|
| NRG-LU002 NCT03137771 IRB 2018-0251 |
Maintenance Systemic Therapy Versus Consolidative Sterotactic Body Radiation Therapy (SBRT) Plus Maintenance Systemic Therapy for Limited Metastatic Non-Small Cell Lung Cancer (NSCLC): A Randomized Phase II/III Trial |
Sub-I: Kevin Redmond Coordinator: Lauren Hendricks; hendrilu@uc.edu |
|
|
BPI-2358-103 NCT02504489 IRB 2015-4653 |
Randomized Phase III Assessment of Second Line Treatment with Docetaxel + Plinabulin Compared to Docetaxel alone in Patients with Advanced Non-Small Cell Lung Cancer with at Least 1 Large Lung Lesion | PI: John Morris Coordinator: Lauren Hendricks; hendrilu@uc.edu |
|
| CALGB30610 NCT00632853 IRB 2013-2796 |
Phase III Comparison of Thoracic Radiotherapy Regimens in Patients with Limited Small Cell Lung Cancer Also Receiving Cisplatin and Etoposide | PI: Kevin Redmond Coordinator: Bree Kinne; kinnebm@ucmail.uc.edu |
|
| MS200095-0022 NCT02864992 IRB 2016-6074 |
A Phase II single-arm trial to investigate tepotinib in stage IIIB/IV adenocarcinoma of the lung with MET exon 14 (METex14) skipping alterations after failure of at least one prior active therapy, including a platinum-doublet-containing regimen | PI: John Morris Coordinator: Lauren Hendricks; hendrilu@uc.edu |
|
| STU022015-069 NCT02468024 IRB 2015-6789 |
A Randomized Phase III Study of Sublobar Resection (SR) versus Stereotactic Ablative Radiotherapy (SAbR) in High Risk Patients with Stage I Non-Small Cell Lung Cancer (NSCLC) | PI: Sandra Starnes Coordinator: Bree Kinne; kinnebm@ucmail.uc.edu |
|
| RRX001-211-01 NCT02489903 IRB 2017-2426 |
A Phase II Study of RRx-001 in Platinum Refractory/Resistant Small Cell Lung Cancer, EGFR TKI Resistant EGFR+ T790M Negative Non-Small Cell Lung Cancer, High Grade Neuroendocrine Tumors and Resistant/Refractory Ovarian Cancer Prior to Re- administration of Platinum Based Doublet Regimens | PI: John Morris Coordinator: Lauren Hendricks; hendrilu@uc.edu |
|
Skin
| Protocol Number | Protocol Title | Contacts | |
|---|---|---|---|
|
EA6174 NCT03712605 IRB 2019-0337 |
A Phase III Randomized Trial of Comparing Adjuvant MK-3475 (Pembrolizumab) to Standard of Care Observation in Completely Resected Merkel Cell Carcinoma | PI: Rekha Chaudhary Coordinator: Melanie Gruen; gruenml@ucmail.uc.edu |
|
| S1801 NCT03698019 IRB 2019-0311 |
A Phase II Randomized Study of Adjuvant Versus Neoadjuvant MK-3475 (Pemborlizumab) for Clinically Detectable Stage III-IV High Risk Melanoma | PI: Rekha Chaudhary Coordinator: Melanie Gruen; gruenml@ucmail.uc.edu |
|
| 2125-MEL-301 NCT03445533 IRB 2018-1638 |
A Randomized Phase III Comarison of IMO-2125 with Ipilimumab versus Ipilimumab Alone in Subjects with Anti-PD-1 Refractory melanoma | PI: Rekha Chaudhary Coordinator: Melanie Gruen; gruenml@ucmail.uc.edu |
|
Expand all
Collapse all
Contact Us
Department of Radiation OncologyBarrett Cancer Center
234 Goodman Street, ML0757
Cincinnati, OH 45267-0757
Phone: 513-584-4775
Fax: 513-584-4007